UI 106
Alternative Names: UI-106Latest Information Update: 23 Mar 2024
At a glance
- Originator Korea United Pharm Inc
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Mar 2024 Early research in Asthma in South Korea (Inhalation) before March 2024 (Korea United Pharm Inc pipeline, March 2024)
- 04 Mar 2024 Early research in Chronic obstructive pulmonary disease in South Korea (Inhalation) before March 2024 (Korea United Pharm Inc pipeline, March 2024)